Circulating tumor cells mirror bone metastatic phenotype in prostate cancer
Metrics: PDF 641 views | HTML 1258 views | ?
Andreas Josefsson1, Karin Larsson1, Marianne Månsson1, Jens Björkman3, Eva Rohlova3,4,5,6, Daniel Åhs1, Helena Brisby2, Jan-Erik Damber1 and Karin Welén1
1Sahlgrenska Cancer Center, Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
2Department of Orthopaedics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
3TATAA Biocenter AB, Gothenburg, Sweden
4Department of Anthropology and Human Genetics, Faculty of Science, Charles University, Prague, Czech Republic
5Laboratory of Gene Expression, Institute of Biotechnology CAS, BIOCEV, Vestec, Czech Republic
6Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
Karin Welén, email: email@example.com
Keywords: liquid biopsies; circulating tumor cells; skeletal metastases of prostate cancer
Received: April 19, 2018 Accepted: May 17, 2018 Published: June 29, 2018
Circulating tumor cells (CTCs) are promising biomarkers in prostate cancer (PC) because they derive from primary tumor and metastatic tissues. In this study, we used quantitative real-time PCR (qPCR) to compare the expression profiles of 41 PC-related genes between paired CTC and spinal column metastasis samples from 22 PC patients that underwent surgery for spinal cord compression. We observed good concordance between the gene expression profiles in the CTC and metastasis samples in most of the PC patients. Expression of nine genes (AGR2, AKR1C3, AR, CDH1, FOLH1, HER2, KRT19, MDK, and SPINK1) showed a significant correlation between the CTC and metastasis samples. Hierarchical clustering analysis showed a similar grouping of PC patients based on the expression of these nine genes in both CTC and metastasis samples. Our findings demonstrate that CTCs mirror gene expression patterns in tissue metastasis samples from PC patients. Although low detection frequency of certain genes is a limitation in CTCs, our results indicate the potential for CTC phenotyping as a tool to improve individualized therapy in metastatic prostate cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.